Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 11/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159290 | 0.86 | PTGER1 (0.61) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4156313 | 0.86 | PTGER1 (0.54) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4164013 | 0.86 | PTGER1 (0.70) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4164130 | 0.85 | PTGER1 (0.53) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4444586 | 0.85 | PTGER1 (0.53) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL13696809 | 0.85 | PTGER1 (0.53) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4153423 | 0.85 | PTGER1 (0.55) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4157965 | 0.85 | PTGER1 (0.45) | PTGER1CYP2C9KDM4ETP53MAPT | |
| SCHEMBL4158601 | 0.84 | PTGER1 (0.57) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4160093 | 0.84 | PTGER1 (0.57) | PTGER1CYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | PTGER1 246/4885CYP2C9 5/4885CNR1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.